OOIR: Observatory of International Research

Papers

(The median citation count of Inflammatory Bowel Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
INFLAMMATORY BOWEL DISEASE IN APPALACHIA: AN INVESTIGATION INTO DISPARATE OUTCOMES WITHIN THE STATE OF KENTUCKY	123
THE ROLE OF GROUP 3 INNATE LYMPHOID CELLS (ILC3) IN GM-CSF/CSF2RB-DEPENDENT INTESTINAL HOMEOSTASIS IN CROHN’S DISEASE	67
UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS	60
GENETIC OVERLAP BETWEEN INFLAMMATORY BOWEL DISEASE AND PARKINSON’S DISEASE IMPLICATES THE ROLE OF ADAPTIVE IMMUNE RESPONSE IN THEIR COMORBIDITY	58
LMT503, A NOVEL THERAPY FOR INFLAMMATORY BOWEL DISEASE THROUGH MACROPHAGE POLARIZATIONS BY METABOLIC REPROGRAMMING OF ACTIVATED MACROPHAGE	57
POINT-OF-CARE INTESTINAL ULTRASOUND FOR THE DETECTION OF POSTOPERATIVE CROHN’S DISEASE ENDOSCOPIC RECURRENCE	53
NIPEP-IBD; A SYNTHETIC PEPTIDE TARGETING NOVEL MOLECULE, INTEGRIN BETA 1, TO RESTITUTE INTESTINAL EPITHELIAL CELLS FOR INFLAMMATORY BOWEL DISEASE (IBD) TREATMENT	52
SECURE ELECTRONIC DOCUMENT SIGNING UPTAKE IN BIOLOGIC PRESCRIBING FOR IMMUNE MEDIATED DISEASES	48
MICROSCOPIC COLITIS IS ASSOCIATED WITH DECREASED BONE DENSITY: A SYSTEMATIC REVIEW AND META-ANALYSIS	43
CHRONIC COLITIS ALTERS BRAIN ACTIVITY BY INDUCING HMGB1-MEDIATED PYROPTOSIS IN MICE	42
IDENTIFYING THE MOST EFFECTIVE TREATMENT ALGORITHM FOR THERAPIES TO TREAT MODERATE TO SEVERE ULCERATIVE COLITIS	38
Reply: MIND the Gap: Psychiatric Conditions in Inflammatory Bowel Disease	36
Postoperative Crohn’s Disease Recurrence Risk and Optimal Biologic Timing After Temporary Diversion Following Ileocolic Resection	36
Pan-enteric Capsule Endoscopy to Characterize Crohn’s Disease Phenotypes and Predict Clinical Outcomes in Children and Adults: The Bomiro Study	35
Prospective Evaluation of the Prediction Score for a Mild Course of Crohn’s Disease (PreMiCC) in Newly Diagnosed Patients With Crohn’s Disease: The PROGNOS Study	35
Letter to the Editors	35
GUT-ASSOCIATED LYMPHOID TISSUE ATTRITION ASSOCIATES WITH RESPONSE TO ANTI-α4β7 THERAPY IN ULCERATIVE COLITIS	34
CHARACTERIZING STROMAL-EPITHELIAL INTERACTIONS IN INTESTINAL STRICTURES	34
THIRTY YEAR EXPERIENCE WITH BARNETT CONTINENT INTESTINAL RESERVOIR: A SINGLE INSTITUTION’S EXPERIENCE	34
TRENDS AND DISPARITIES IN THE BURDEN OF INFLAMMATORY BOWEL DISEASE IN MISSOURI OVER THREE DECADES	34
Increasing Exposure to Inflammatory Bowel Diseases Education in Gastroenterology Fellowship: The Pilot IBD 101 Experience	34
ESTABLISHING CLINICAL C-REACTIVE PROTEIN LEVELS IN SWEAT BASED WEARABLES FOR INFLAMMATORY BOWEL DISEASE SUBJECTS WITH ULCERATIVE COLITIS	33
EFFICACY AND SAFETY OF UPADACITINIB FOR ACUTE SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS	32
LOCAL INFLAMMATION IMPRINTS AN UNRESTRAINED TISSUE-ADAPTED PHENOTYPE ON INTESTINAL EOSINOPHILS	32
CARDIAC MANIFESTATIONS OF MESALAMINE USE IN INFLAMMATORY BOWEL DISEASE: CASE REPORT AND REVIEW OF THE LITERATURE	30

PATIENT ATTITUDES TO MAGNETIC RESONANCE IMAGING IN PERIANAL FISTULIZING CROHNS DISEASE: A GLOBAL SURVEY	29
COMPARATIVE EFFICACY OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UC PATIENTS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	29
DELAYS IN THE ADMINISTRATION OF BIOLOGIC THERAPIES AND ADVERSE OUTCOMES IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE STUDY	29
COMPARATIVE EFFECTIVENESS OF ORAL JANUS KINASE INHIBITORS VERSUS VEDOLIZUMAB IN ULCERATIVE COLITIS AFTER ANTI-TNF THERAPY FAILURE: A SYSTEMATIC REVIEW AND META-ANALYSIS	29
IL-23-ACTIVATED CELLS PREDICT RESPONSE TO RISANKIZUMAB IN CROHN’S DISEASE	29
EFFICACY OF RISANKIZUMAB IN ACHIEVING CLINICAL REMISSION IN CROHN’S DISEASE: A COMPREHENSIVE META-ANALYSIS	28
REGIONAL AND SOCIOECONOMIC DISPARITIES IN ULCERATIVE COLITIS AND COLORECTAL CANCER RELATED MORTALITY IN THE UNITED STATES AND TEXAS: A 21 YEAR RETROSPECTIVE STUDY	28
MENOPAUSE AND INFLAMMATORY BOWEL DISEASE: SYSTEMATIC REVIEW	28
MICROBIAL TRIMETHYLAMINE HOST TRACE AMINE ASSOCIATED RECEPTOR 5 (TAAR5) SIGNALING EXERTS PRO-FIBROTIC PROPERTIES IN IBD	27
THE IMPACT OF OBESITY ON RESPONSE TO INFLIXIMAB SALVAGE THERAPY IN PATIENTS WITH ACUTE SEVERE ULCERATIVE COLITIS	27
ENHANCED ANTIOXIDANT SIGNALING BY MITOCHONDRIAL-TARGETED DRUG AUPHOS DRIVES ATTENUATION OF COLITIS	27
REAL-WORLD FEASIBILITY AND IMPACT OF DECENTRALIZED TRIAL RECRUITMENT FOR PATIENTS WITH INFLAMMATORY BOWEL DISEASE AT THREE ACADEMIC CENTERS	27
GLOBAL BURDEN OF IBD: A COMPARATIVE ANALYSIS OF THE TWO MOST AFFECTED REGIONS (1990-2021)	26
CLINICAL OUTCOMES FOR EOSINOPHILIC ESOPHAGITIS AMONG CHILDREN AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE	25
USTEKINUMAB-INDUCED ANCA-VASCULITIS IN A PATIENT WITH CROHN’S DISEASE: A CASE REPORT	25
A RANDOMIZED PLACEBO-CONTROLLED TRIAL OF ALGINATE INTAKE AFTER FECAL MICROBIOTA TRANSPLANTATION FOR ULCERATIVE COLITIS	25
BIFIDOBACTERIUM STRAINS MAY SUPPRESS GROWTH OF PRO-INFLAMMATORY CANDIDA SPECIES IN PATIENTS WITH ULCERATIVE COLITIS	25
FECAL PROTEOLYTIC ACTIVITY AND SYMPTOMATIC STATUS ARE ASSOCIATED IN CROHN’S DISEASE	24
RARE PULMONARY MANIFESTATIONS IN A PATIENT WITH CROHN’S DISEASE	24
CHARACTERIZING LATE-ONSET CROHN’S DISEASE: INSIGHTS FROM A RETROSPECTIVE COHORT STUDY	24
LYSINE ACETYLTRANSFERASES OF BOTH P300/CBP (P300 AND PCAF) AND MYST (TIP60) FAMILIES BUTYRYLATE BETA CATENIN AT LYSINE 345 AND INCREASE ITS TRANSCRIPTIONAL ACTIVITY	24
INFECTION RATES IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH A SPHINGOSINE 1-PHOSPHATE RECEPTOR MODULATOR	24
Role of Energy Metabolism and Mitochondrial Function in Inflammatory Bowel Disease	23
DAILY ASPIRIN USE IN ULCERATIVE COLITIS: A DOUBLE-EDGED SWORD INCREASING MORTALITY AND SEVERE OUTCOMES WHILE MODESTLY REDUCING COLORECTAL CANCER RISK	23
THE CROHN’S AND COLITIS DISTRESS SCALE: ASSESSING THE DOMAINS OF IMPACT IN YOUTH WITH IBD	23
REAL-WORLD EXPERIENCE WITH CURCUMIN-QINGDAI IN MANAGING ADULTS WITH ACTIVE ULCERATIVE COLITIS	23
Dietary Inflammatory Indices Are Not Associated With Inflammatory Bowel Disease Incidence and Progression	22
Ileocolic Resection for Crohn Disease: The Influence of Different Surgical Techniques on Perioperative Outcomes, Recurrence Rates, and Endoscopic Surveillance	22
Eicosatetraynoic Acid and Butyrate Regulate Human Intestinal Organoid Mitochondrial and Extracellular Matrix Pathways Implicated in Crohn’s Disease Strictures	22
GENERATION OF ANTIGEN-SPECIFIC REGULATORY T CELLS BYLACTOBACILLUS SPECIES	22
Regional Gray Matter Volume Changes in Brains of Patients With Ulcerative Colitis	22
Preoperative Use of Multiple Advanced Therapies Is Not Associated With Endoscopic Inflammatory Pouch Diseases	22
INFLAMMATORY BOWEL DISEASE IN YOUTH UNDER 20 FROM 1990-2019: A GLOBAL PERSPECTIVE ON REGIONAL AND NATIONAL VARIATIONS FROM THE GBD 2019 ANALYSIS	22
COMBINATION BIOLOGIC AND SMALL MOLECULE THERAPY FOR REFRACTORY ULCERATIVE COLITIS	21
Pharmacogenomic Assessment of Genes Implicated in Thiopurine Metabolism and Toxicity in a UK Cohort of Pediatric Patients With Inflammatory Bowel Disease	21
ALTERED MICROBIAL BIOGEOGRAPHY IN INNATE IMMUNE-MEDIATED COLITIS	21
IBD AND THE PATIENT-PROVIDER RELATIONSHIP: DOES TRUST IMPACT TELEMEDICINE UTILIZATION?	21
Correction to: Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease	21
MATRIX METALLOPROTEINASE (MMP-9) INDUCED INCREASE IN INTESTINAL EPITHELIAL TIGHT JUNCTION BARRIER IS MEDIATED BY EGFR ACTIVATION	21
KLEBSIELLA PNEUMONIAE IN THE COLONIC MUCUS LAYER INFLUENCESCLOSTRIDIODES DIFFICILE PATHOGENESIS	21
IMPACT OF CURRENT AND FORMER SMOKING ON THE RISK OF ULCERATIVE COLITIS AMONG FAMILY HISTORY POSITIVE AND NEGATIVE INDIVIDUALS; EVIDENCE FOR GENE-SMOKING INTERACTION FROM LARGE SCALE POPULATION-BASED C	21
SELECTION OF MICROBIOME-DERIVED PEPTIDES THROUGH MULTI-TECHNOLOGY META-ANALYSIS, BINDING, AND FUNCTIONAL ASSAYS, IDENTIFIES PEPTIDES WITH THERAPEUTIC POTENTIAL THAT MODULATE IMMUNE RESPONSES AND DISEA	21
VEDOLIZUMAB, USTEKINUMAB AND TOFACITINIB AS TRIPLE THERAPY FOR ULCERATIVE COLITIS	20
Safety and Efficacy of Fecal Microbiota, Live-jslm (REBYOTA®), for the Prevention of Recurrent Clostridioides difficile Infection in Participants With Inflammatory Bowel Disease in PUNCH CD3-OL	20
TRANSPORTATION ACCESS AND DELAY IN DIAGNOSIS FOR PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS	20
The Consequences of Preterm Birth in the Children of Mothers with Inflammatory Bowel Disease: A Nationwide Cohort Study	20
AUPHOS, A NOVEL THERAPEUTIC THAT IMPROVES MITOCHONDRIAL FUNCTION AND AMELIORATES CHRONIC COLITIS	20
Correction to: Efficacy, Safety, and Tolerability of  Omilancor in a Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Ulcerative Colitis	20
BURDEN OF ILLNESS OF OSTEOPOROTIC FRACTURES COMPARED TO OTHER SERIOUS DISEASES AMONG IBD PATIENTS	19
UTILITY OF FIBROSCAN IN ULCERATIVE COLITIS?	19

Significant Racial and Ethnic Disparities Exist in Health Care Utilization in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis	19
Identification of Lipocalin 2 as a Potential Ferroptosis-related Gene in Ulcerative Colitis	19
LONG TERM ADVERSE HEALTH OUTCOMES IN OFFSPRING FROM MOTHERS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE POPULATION BASED STUDY IN KOREA	19
FEAR OF THE COVID-19 PANDEMIC IN ADOLESCENTS AND YOUNG ADULTS WITH INFLAMMATORY BOWEL DISEASE: RELATIONSHIP TO PSYCHOLOGICAL AND PHYSICAL OUTCOMES	19
INCIDENTALLY DIAGNOSED ASYMPTOMATIC CROHN’S DISEASE: LONG-TERM CLINICAL OUTCOMES OF UNTREATED PATIENTS	19
AHR EXPRESSION ON VIL1-EXPRESSING COLONIC EPITHELIAL CELLS IS ESSENTIAL FOR I3C-MEDIATED PROTECTION AGAINST COLITIS	19
EFFECTIVENESS OF ANTI-TNF THERAPY COMPARED TO IMMUNE MODULATOR FOR PREVENTION OF SURGICAL RECURRENCE IN PEDIATRIC CD	19
Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab	19
INCREASE IN MK2 ACTIVITY IN CROHN’S DISEASE: ROLE IN THE INFLAMMATORY ACTIVATION OF FIBROBLASTS	18
MIRIKIZUMAB REDUCES ABDOMINAL PAIN IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE	18
NOVEL FUNCTION OF MYELOID METHYLTRANSFERASE SMYD5 IN INFLAMMATORY BOWEL DISEASE PROGRESSION	18
DOSE ESCALATION OF BIOLOGIC THERAPIES IN BIOLOGIC TREATMENT-NAÏVE ADULT PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE ODESSA DATABASE STUDY	18
High Healthcare Costs in Childhood Inflammatory Bowel Disease: Development of a Prediction Model Using Linked Clinical and Health Administrative Data	18
EFFECTS OF DELAYED ENDOSCOPIES IN INFLAMMATORY BOWEL DISEASE PATIENTS DURING THE COVID-19 PANDEMIC	17
INDOLENT SYSTEMIC MASTOCYTOSIS MASQUERADING AS CHRONIC ANEMIA IN ULCERATIVE COLITIS: A CASE STUDY	17
MUCOSAL SINGLE-CELL PROFILING OF CROHN’S-LIKE DISEASE OF THE POUCH REVEALS COMMON PATHOGENICS AND THERAPEUTIC TARGETS	17
BUDGET IMPACT OF MIRIKIZUMAB-MRKZ IN THE TREATMENT OF ADULT PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS IN THE UNITED STATES	17
CREEPING FAT-DERIVED FIBROBLASTS PARTICIPATE IN INTESTINAL FIBROSIS IN A NOVEL MOUSE MODEL OF INTESTINAL STRICTURES	17
DEPRESSION MAY BE A STRONGER UNIQUE PREDICTOR OF FATIGUE THAN SELF-REPORTED IBD DISEASE ACTIVITY	17
DEVELOPMENT OF A PERSONALIZED HUMAN PANETH CELL MODEL USING INTESTINAL ORGANOIDS	17
SHORT NONCODING RNAS AS PREDICTIVE BIOMARKERS FOR THE DEVELOPMENT FROM INFLAMMATORY BOWEL DISEASE UNCLASSIFIED TO CROHN’S DISEASE OR ULCERATIVE COLITIS	17
GRANZYME A-PRODUCING CD4 T CELLS ARE DRIVERS OF IMMUNE CHECKPOINT BLOCKADE-INDUCED COLITIS	17
GROUP 3 INNATE LYMPHOID CELLS RELY ON ER STRESS RESPONSE FOR CYTOKINE PRODUCTION IN IBD	17
COMPARING MAGNETIC RESONANCE ENTEROGRAPHY AND ENDOSCOPY FINDINGS TO QUANTATATIVE MAGENTIC RESONANCE IMAGING IN PEDIATRIC CROHN’S DISEASE	17
REAL-WORLD EXPERIENCE AND PERSPECTIVES ON THE TREATMENT OF ULCERATIVE COLITIS: RESULTS FROM A HEALTHCARE PROVIDER SURVEY	17
P2Y1 RECEPTOR SIGNALING INFLUENCES EPITHELIAL RESPONSE TO INTESTINAL INFLAMMATION	16
IDENTIFYING THE ROLE OF ACINETOBACTER CALCOACETICUS IN DRIVING INTESTINAL INFLAMMATION	16
REPRESSED MITOCHONDRIAL FUNCTION LIMITS CRYPT FISSIONING IN INFLAMMATORY BOWEL DISEASE	16
PATIENT DECISION MAKING ABOUT UTILIZATION OF TREATMENT AND MANAGEMENT METHODS: TOWARD ENHANCED PROMOTION OF PREVENTIVE SELF-MANAGEMENT FOR ULCERATIVE COLITIS	16
VALIDATION OF AN INFLIXIMAB POPULATION PHARMACOKINETIC MODEL FOR MAINTENANCE DOSING IN PEDIATRIC PATIENTS WITH INFLAMMATORY BOWEL DISEASE	16
UPREGULATION OF SERPINE1/PAI-1 INDUCED BY IL-33 CONTRIBUTES TO INTESTINAL FIBROSIS IN A CROHN’S DISEASE-LIKE ILEITIS MODEL	16
LOWER MORTALITY RISK WITH COMBINATION THERAPY WITH ANTI-TNF THERAPY AND THRIOPURINE COMPARED TO THIOPURINE ALONE IN ELDERLY PATIENTS WITH UC	16
THE COST OF INFLAMMATORY BOWEL DISEASE: A POPULATION-BASED ANALYSIS OF ADMINISTRATIVE DATA	16
VARIOUS ADHERENT-INVASIVE E. COLI (AIEC) AND NON-AIEC STRAINS ISOLATED FROM CROHN’S DISEASE PATIENTS GROW DIFFERENTLY WITH RUMINOCOCCUS GNAVUS PRE-DIGESTED MUCUS AND R. GNAVUS-REL	16
LIQUID-BIOPSY FOR ASSESSING SEVERITY OF INFLAMMATORY BOWEL DISEASE VIA PLASMA MICROBIAL CELL-FREE DNA	16
YOUTUBE AND INFLAMMATORY BOWEL DISEASE, A 10-YEAR UPDATE	16
DIETARY INTERVENTION AS A NOVEL TOOL TO IMPROVE DIAGNOSTIC ACCURACY OF PATENCY CAPSULE IN CROHN'S DISEASE PATIENTS	16
VEDOLIZUMAB RESPONSE AND NON-RESPONSE IN ULCERATIVE COLITIS: INSIGHTS FROM SPATIAL TRANSCRIPTOMICS	16
MICROBIAL REPRESENTATION ASSOCIATION WITH LEVEL OF SHORT CHAIN FATTY ACIDS IN SMALL BOWEL	16
BIOACTIVE INTERLEUKIN-1 DETECTED IN IBD PATIENT INTESTINAL BIOPSIES IS A HALLMARK OF ULCERS AND CORRELATES WITH TRANSCRIPTOMIC ASSESSMENTS, INCLUDING AN ULCER-ASSOCIATED GENE MODULE	16
SAFETY OF ANTI-TUMOR NECROSIS FACTOR AGENTS COMPARED TO USTEKINUMAB AND VEDOLIZUMAB IN ELDERLY PATIENTS WITH ULCERATIVE COLITIS	16
EXPLORING THE RELATIONSHIP BETWEEN PATIENT SYMPTOMS AND PROVIDER GOALS FOR MUCOSAL HEALING IN IBD: INSIGHTS FROM THE IBD QORUS SURVEY DATA	16
HOSPITAL READMISSION AND MORTALITY RATES IN PATIENTS WITH CONCURRENT DEPRESSION AND INFLAMMATORY BOWEL DISEASE: INSIGHTS FROM THE NATIONAL READMISSIONS DATABASE, 2016–2019	15
EPITHELIAL MITOCHONDRIAL DYSFUNCTION IN CHRONIC POUCHITIS	15
RANDOMIZED, DOUBLE-BLIND, PLACEBO (PBO)-CONTROLLED, SINGLE- AND MULTIPLE-DOSE PHASE 1 STUDY OF VE202, A DEFINED BACTERIAL CONSORTIUM FOR TREATMENT OF IBD: SAFETY AND COLONIZATION DYNAMICS OF A NOVEL L	15
CHARACTERIZING THE JOHNS HOPKINS INFLAMMATORY BOWEL DISEASE COHORT USING OMOP CDM	15
PERFUSED IN VITRO INTESTINE TISSUE FOR STUDYING INFLAMMATORY BOWEL DISEASE RESPONSE TO DRUG THERAPIES	15
VEDOLIZUMAB DOES NOT ALTER IMMUNOGLOBULIN LEVELS IN BREASTMILK OF MOTHERS WITH IBD	15
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS	15
THE ONSET AND SEVERITY OF ULCERATIVE COLITIS IN IL-10 -/- MICE IS NOT DEPENDENT ON FECAL MICROBIOTA TRANSPLANTATION FROM ULCERATIVE COLITIS PATIENTS	15
ASSOCIATION OF INFLAMMATORY BOWEL DISEASE AND AUTOIMMUNE PRIMARY ADRENAL INSUFFICIENCY	15
ASSESSMENT OF THE IMMUNE CELL LANDSCAPE IN INFLAMMATORY BOWEL DISEASE	15
USING R TO ADVANCE PATIENT-CENTRIC RESEARCH IN THE STUDY OF A PROSPECTIVE ADULT RESEARCH COHORT	15
ACCELERATED INFLIXIMAB INFUSION SAFETY AND TOLERABILITY IS NON-INFERIOR TO STANDARD INFUSION PROTOCOL IN INFLAMMATORY BOWEL DISEASE PATIENTS – A RANDOMIZED CONTROLLED STUDY	15
A PRECLINICAL MODEL OF STENOTIC CROHN’S DISEASE FOR THE STUDY OF MECHANISMS OF MOTILITY DYSFUNCTION IN IBD	14
FEASIBILITY OF A NURSE AND DIETITIAN-LED IBD SURGICAL PREHABILITATION PROGRAM	14
REAL-WORLD EXPERIENCE FOR BIOLOGIC USE IN IBD IN THAI: A SINGLE-CENTER EXPERIENCE	14
NOVEL INSIGHTS INTO THE MECHANISM OF ACTION OF EXCLUSIVE ENTERAL NUTRITION IN CROHN’S DISEASE: PRE-CLINICAL STUDY IN A RODENT MODEL OF CROHN’S-LIKE COLITIS	14
Prior Appendectomy Is Associated With a Milder Clinical Course in Crohn’s Disease: A Nationwide Population-based Cohort Study	14
A NURSE LED INTERVENTION TO IMPROVE ACCESS TO CARE USING A TELEPHONE TRIAGE ALGORITHM	14
ENGAGING PATIENTS IN INFLAMMATORY BOWEL DISEASE CARE — WHAT DETERMINES ACTIVE PARTICIPATION?	14
A PHASE II OPEN LABEL STUDY OF NEIHULIZUMAB, AN ANTI-CD162 (PSGL-1) ANTIBODY, IN PATIENTS WITH MODERATE TO SEVERE ACTIVE, ANTI-TNFα AND/OR ANTI-INTEGRIN REFRACTORY ULCERATIVE COLITIS	14
The Relationship Between Opioid Use and Healthcare Utilization in Patients With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis	14
COMMUNICATING NEEDS AND FEATURES OF IBD EXPERIENCES (CONFIDE) SURVEY: BURDEN AND IMPACT OF BOWEL URGENCY ON PATIENTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS	14
DEVELOPMENT OF AN OPTIMAL MACHINE LEARNING MODEL USING TREATMENT NAÏVE DIAGNOSTIC PATHOLOGY IMAGES TO PREDICT STEROID-FREE CLINICAL REMISSION AT ONE YEAR IN PEDIATRIC ULCERATIVE COLITIS	14
AMINOSALICYLATE USE IN PEDIATRIC PATIENTS WITH CROHN’S DISEASE	14
PERSISTENCE WHILE ON LABELED MAINTENANCE DOSE AMONG BIO-EXPERIENCED PATIENTS WITH CROHN'S DISEASE INITIATED ON USTEKINUMAB COMPARED TO ADALIMUMAB	14
Increased Bacterial Proteolytic Activity Detected Before Diagnosis of Ulcerative Colitis	14
Germline Alterations in Patients With IBD-associated Colorectal Cancer	14
SPATIAL CONCORDANCE OF LEFT AND RIGHT COLON FINDINGS IN PEDIATRIC PATIENTS WITH ULCERATIVE COLITIS AFTER TREAMTENT	14
GUT-BIOME MODULATION WITH HUMAN MILK OLIGOSACCHARIDE (HMO) BASED SYNBIOTIC FOR A COMPLETE AND DEEP REMISSION IN CROHN’S DISEASE: A CASE STUDY	13
EPITHELIAL DUOX2 ACTIVATION INCREASES GUT PERMEABILITY AND BACTERIAL TRANSLOCATION THAT IS RESCUED WITH BUTYRATE SUPPLEMENTATION	13
Impact of Psychosocial and Neurodevelopmental Disorders on Pediatric Ulcerative Colitis: A Single-Center, Retrospective, Observational Study	13
Improving Brain–Gut Studies in Crohn’s Disease: Methodological Considerations	13
The Pathogenicity and Synergistic Action of Th1 and Th17 Cells in Inflammatory Bowel Diseases	13
Risankizumab Is Effective for the Management of Crohn’s Disease of the Pouch	13
Deployment of an Artificial Intelligence Histology Tool to Aid Qualitative Assessment of Histopathology Using the Nancy Histopathology Index in Ulcerative Colitis	13
hsa_circ_0015388 Reduces Macrophage Derived Reactive Oxygen Species in Crohn’s Disease	13
S1P Lyase Inhibition Increased Intestinal S1P, Disrupted the Intestinal Barrier and Aggravated DSS-Induced Colitis	13
Stromal Cell Subsets Show Model-Dependent Changes in Experimental Colitis and Affect Epithelial Tissue Repair and Immune Cell Activation	13

Ileoanal Pouch–Related Fistulas: A Narrative Review	13
Changes in Editorial Leadership	13
Reply to “Improving Brain-Gut Studies in Crohn’s Disease: Methodological Considerations”	13
Impact of 5-Aminosalicylic Acid on Ustekinumab in Inflammatory Bowel Disease: A Retrospective Medical Claims Analysis	13
NHE3 Controls Proliferation and Migration of Colonic Epithelial Cells	13
Eleven Grand Challenges for Inflammatory Bowel Disease Genetics and Genomics	13
A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease	13
Characterization of Mycophenolate Mofetil Gastrointestinal Toxicity and Risk Factors for Severe Disease and Poor Prognosis	12
The Neglected Gut Microbiome: Fungi, Protozoa, and Bacteriophages in Inflammatory Bowel Disease	12
De Novo Pediatric Ulcerative Colitis Triggered by SARS-CoV-2 Infection: a Tale of 2 Sisters	12
Acute Severe Ulcerative Colitis and Cytomegalovirus During Pregnancy: A Case Report	12
A Prospective Trial with Long Term Follow-up of Patients With Severe, Steroid-Resistant Ulcerative Colitis Who Received Induction Therapy With Cyclosporine and Were Maintained With Vedolizumab	12
Ultrasound-Tomographic Image Fusion: A Novel Imaging Technique for Follow-Up of Penetrating Complications of Crohn’s Disease	12
A Case of Ulcerative Colitis Relapse Characterized by Systemic Type I Interferon Responses after COVID-19 Vaccination	12
High Degree of Practice Variability in Colonic Dysplasia Surveillance for Patients With Inflammatory Bowel Disease	12
Multisegmental Hypoganglionosis: A Rare Cause of Recurrent Bowel Obstruction and Intestinal Ulcers	12
Virtual Chromoendoscopy vs High-definition White Light Endoscopy Using iSCAN	12
Immunological Regulation of Intestinal Fibrosis in Inflammatory Bowel Disease	12
Squamous Cell Carcinoma of the Pouch	12
Multifocal Pyoderma Gangrenosum at Presentation in a Patient With Acute Severe Ulcerative Colitis	12
Selecting High-Risk Patients With Pediatric Crohn’s Disease for Top-Down Anti-TNF as per the 2021 ECCO-ESPGHAN Guidelines: A 5-Year Nationwide Retrospective Analysis From Scotland (2016-2020)	12
Risk Factors for Voluntary Childlessness in Men and Women With Inflammatory Bowel Disease	12
Hyperbaric Oxygen as Successful Monotherapy for a Severe Ulcerative Colitis Flare	11
Bidirectional Correlations Between Health Confidence and Inflammatory Bowel Disease Activity: A Nationwide Longitudinal Cohort Study	11
Response to the Letter to the Editor: “Re-Revisiting the Association Between Inflammatory Bowel Disease and Parkinson’s Disease”	11
Reply to “Biologics Are Effective in the Management of Inflammatory Bowel Disease Following Liver Transplantation in Combination With Antirejection Therapy”	11
Vedolizumab Therapy for Refractory Eosinophilic Enteritis: A Case of Success	11
The Incidence of Pouch Neoplasia Following Ileal Pouch–Anal Anastomosis in Patients With Inflammatory Bowel Disease	11
Early Biologic Treatment Decreases Risk of Surgery in Crohn’s Disease but not in Ulcerative Colitis: Systematic Review and Meta-Analysis	11
Reply: Frail Phenotype in Patients With Inflammatory Bowel Disease	11
Unilateral Painless Vulval Swelling Presenting as an Adverse Reaction to Adalimumab	11
Gender-Based Differences in Response to Tumor Necrosis Factor Inhibitor Therapies for Ulcerative Colitis: Individual Participant Data Meta-Analyses of Clinical Trials	11
Label-Free Characterization and Quantification of Mucosal Inflammation in Common Murine Colitis Models With Multiphoton Imaging	11
A Novel Probiotic Combination Ameliorates Crohn’s Disease–Like Ileitis by Increasing Short-Chain Fatty Acid Production and Modulating Essential Adaptive Immune Pathways	11
Safety Analysis of Preoperative Anti-TNF-α Therapy in Pediatric IBD After Intestinal Resection: A Systematic Review and Meta-analysis	11
Young Adult Male Patients With Childhood-onset IBD Have Increased Risks of Compromised Cortical and Trabecular Bone Microstructures	11
Is it a Flare? Acute Appendicitis in Ulcerative Colitis Patient Found on Routine Screening Colonoscopy	11
Opioid Legislation in Patients With Inflammatory Bowel Disease: A State-wide Retrospective Cohort Study	11
Increased Expression of Interleukin-13 Receptor in Ileum Associated With Nonresponse to Adalimumab in Ileal Crohn’s Disease	11
Mindfulness Intervention Decreases Frequency and Severity of Flares in Inactive Ulcerative Colitis Patients: Results of a Phase II, Randomized, Placebo-Controlled Trial	11
Improving the Computer-Aided Estimation of Ulcerative Colitis Severity According to Mayo Endoscopic Score by Using Regression-Based Deep Learning	11
A Serum Biomarker Panel Can Accurately Identify Mucosal Ulcers in Patients With Crohn’s Disease	11
Utilization of Colonoscopy Following Treatment Initiation in U.S. Commercially Insured Patients With Inflammatory Bowel Disease, 2013-2019	11
The Prevalence of Inflammatory Bowel Disease in Greenland	11
Crohn’s Disease Patients Uniquely Contain Inflammatory Responses to Flagellin in a CD4 Effector Memory Subset	11
Invasive Therapeutic Strategies for Stricturing Crohn’s Disease in Childhood: A Systematic Review and Meta-Analysis	10
Following Through: The Impact of Culinary Medicine on Mediterranean Diet Uptake in Inflammatory Bowel Disease	10
Crohn’s Disease Complicated by an Ileo-urachal Fistula	10
Treatment Decision-making in Chinese Inflammatory Bowel Disease Patients	10
Novel Patient-centered Educational Panel Enhances Preclinical Medical Student Understanding of IBD Beyond What Can Be Learned in a Traditional Classroom	10
A Novel 8-Predictors Signature to Predict Complicated Disease Course in Pediatric-onset Crohn’s Disease: A Population-based Study	10
Causal Relationship Between Estimated Glomerular Filtration Rate and Inflammatory Bowel Disease: Genetic Evidence From Bidirectional Mendelian Randomization Analysis	10
Secondary Indicators for an Evaluation and Guidance System for Quality of Care in Inflammatory Bowel Disease Centers: A Critical Review of the Inflammatory Bowel Disease Quality of Care Center	10
Clinical Phenotype and Disease Course of Inflammatory Bowel Disease: A Comparison Between Sporadic and Familial Cases	10
SARS-CoV-2 Infection in the Follow-Up of a Population With Inflammatory Bowel Disease	10
Effects of JAK1-Preferential Inhibitor Filgotinib on Circulating Biomarkers and Whole Blood Genes/Pathways of Patients With Moderately to Severely Active Crohn’s Disease	10
10-Year Trend of Abdominal Magnetic Resonance Imaging Compared With Abdominal Computed Tomography Scans in Inflammatory Bowel Disease	10
3D Imaging and Printing in Inflammatory Bowel Diseases: Limitations, Barriers, and Opportunities Toward “Haute Couture” Surgical Approaches	10
Are the New Biologics Effective in the Management of Postoperative Crohn’s Disease?	10
Long-term Disease Behavior and Surgical Intervention Analysis in Hospitalized Patients With Crohn’s Disease in China: A Retrospective Cohort Study	10
Food-Based Interventions as Therapy for Inflammatory Bowel Disease: Important Steps in Diet Trial Design and Reporting of Outcomes	10
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review	10
Impact of Thiopurine Exposure on Immunogenicity to Infliximab Is Negligible in the Setting of Elevated Infliximab Concentrations	10
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients’ Association	10
Challenging the Surge of Inflammatory Bowel Disease: The Role of the China Crohn’s and Colitis Foundation in the Healthcare Landscape of Inflammatory Bowel Disease	10
Interventions to Improve Adherence to Preventive Care in Inflammatory Bowel Disease: A Systematic Review	10
Microbial and Metabolite Signatures of Stress Reactivity in Ulcerative Colitis Patients in Clinical Remission Predict Clinical Flare Risk	10
New Insights into the Pathogenesis of Intestinal Fibrosis in Inflammatory Bowel Diseases: Focusing on Intestinal Smooth Muscle Cells	10
Novel mRNA Signature for Anti-TNF-α Therapy Primary Response in Patients With Ulcerative Colitis	10
Real-world Evidence Comparing Tofacitinib and Vedolizumab in Anti-TNF-experienced Patients With Ulcerative Colitis	9
Children and Adolescents Diagnosed With Inflammatory Bowel Disease Are at Increased Risk of Developing Diseases With a Possible Autoimmune Pathogenesis	9
Granulomas in Diagnostic Biopsies Associated With High Risk of Crohn’s Complications—But May Be Preventable	9
Response to the Letter to the Editor: “Pyoderma Gangrenosum in An Ulcerative Colitis Pediatric Patient During Vedolizumab Therapy Successfully Treated With Oral Cyclosporine”	9
Clinical Pharmacist Counselling Improves Long-term Medication Safety and Patient-reported Outcomes in Anti-TNF-treated Patients With Inflammatory Bowel Diseases: The Prospective, Randomized AdPhaNCED	9
Bowel Damage and Disability in Crohn’s Disease: Is it Really Two Birds with One Stone?	9
Home-based Biologic Infusions for Inflammatory Bowel Disease: Are We Ready for Prime Time?	9
Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12	9
Consensus Statement on Managing Anxiety and Depression in Individuals with Inflammatory Bowel Disease	9
Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease	9
Letter: Enhancing the Rigor of Research on Herpes Zoster Risk in IBD Patients Post-SARS-CoV2: Recommendations for Global and Detailed Analyses—Authors’ Reply	9
Undetected Dysplasia at Colectomy in Patients With Inflammatory Bowel Diseases. What Are We Missing?	9
Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD	9
Gluteal Sinus Presenting as the Initial Symptom in a Patient With Crohn’s Disease	9
Short-Term Use of Upadacitinib in Combination With Biologic Therapy for Inducing Clinical Remission in Patients With Active Inflammatory Bowel Disease	9
Safety of Biologic and Small Molecule Therapy for Inflammatory Bowel Disease Among Solid Organ Transplant Recipients: Systematic Review and Meta-Analysis	9
Efficacy of Vaccination and Revaccination Against Hepatitis B Virus Using 2 Different Strategies in Patients With Inflammatory Bowel Disease	9
The Long View: 2-Year Outcomes of Mirikizumab for Ulcerative Colitis	9
Long-term Effects of Teduglutide on Intestinal Mucosa in a Patient With Crohn’s Disease and Short Bowel Syndrome: Clinical, Endoscopic and Histological Data Compared	9
Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise	9
Performance of ASCVD Risk Prediction Models in Individuals With Inflammatory Bowel Disease: A UK Biobank Study	9
Solute Transporter OCTN1/Slc22a4 Affects Disease Severity and Response to Infliximab in Experimental Colitis: Role of Gut Microbiota and Immune Modulation	9
The Utility of Intestinal Ultrasound in a Case of Microscopic Colitis	9
Increased Risks for Suicide, Self-Harm, Substance Use, and Psychiatric Disorders in Adults With Inflammatory Bowel Disease: A Nationwide Study in the United States From 2007 to 2017	9
The Future of Therapeutic Drug Monitoring in Inflammatory Bowel Disease: An Emphasis on the Essential Ingredients	9
Limiting Opioid Use for Patients Who Are Hospitalized for Inflammatory Bowel Disease Exacerbations	9